The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience
- 1 November 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 9 (11), 2229-2234
- https://doi.org/10.1111/j.1538-7836.2011.04493.x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIaEuropean Journal of Clinical Investigation, 2009
- Immune tolerance: critical issues of factor dose, purity and treatment complicationsHaemophilia, 2006
- Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastographyHaemophilia, 2006
- Inhibitors to Factor VIII/IX: Treatment of Inhibitors—Immune Tolerance InductionPublished by Wiley ,2005
- Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia AThrombosis and Haemostasis, 2005
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institutionHaemophilia, 2001
- Immune Tolerance Therapy for HaemophiliaDrugs, 2000
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992